PRPH (ProPhase Labs) 3-Year Dividend Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is ProPhase Labs 3-Year Dividend Growth Rate?

ProPhase Labs PRPH -13.00% 3-Year Dividend Growth Rate is 0.00% as of Jun. 2026. The stock has 6 warning signs investors should review. Among 49 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 2040814.29% on this metric.

ProPhase Labs's Dividends per Share for the three months ended in Jun. 2026 was $0.00.

The historical rank and industry rank for ProPhase Labs's 3-Year Dividend Growth Rate or its related term are showing as below:

PRPH's 3-Year Dividend Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 10.1
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

ProPhase Labs's Dividend Payout Ratio for the three months ended in Jun. 2026 was 0.00. As of today, ProPhase Labs's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

ProPhase Labs  (OTCPK:PRPH) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

ProPhase Labs's Dividend Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Jun. 2026 )/ EPS without NRI (Q: Jun. 2026 )
=0/ -0.236
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProPhase Labs 3-Year Dividend Growth Rate Related Terms>

PRPH vs NOTVQ, NSTM, FUNI: 3-Year Dividend Growth Rate Comparison

For the Diagnostics & Research subindustry, ProPhase Labs's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProPhase Labs 3-Year Dividend Growth Rate vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's 3-Year Dividend Growth Rate falls into.


ProPhase Labs 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Dividend Growth Rate of 0.00% mean?
ProPhase Labs (PRPH) has a 3-Year Dividend Growth Rate of 0.00% as of Jun. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on ProPhase Labs and its competitors. According to the industry distribution chart, ProPhase Labs ranks #999999 out of 49 companies in the Medical Diagnostics & Research industry.
Is ProPhase Labs' 3-Year Dividend Growth Rate too high?
ProPhase Labs' current 3-Year Dividend Growth Rate is 0.00%. Based on the distribution chart, ProPhase Labs ranks #999999 out of 49 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' 3-Year Dividend Growth Rate compare to NOTVQ and NSTM?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #999999 out of 49 companies for 3-Year Dividend Growth Rate. This places ProPhase Labs in the lower half of its industry. The industry median 3-Year Dividend Growth Rate is 10.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year Dividend Growth Rate among Medical Diagnostics & Research companies is 10.10, based on 49 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year Dividend Growth Rate is 10.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current 3-Year Dividend Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.59, compared to a current price of $0.02 — trading 97.1% below its estimated fair value. The current 3-Year Dividend Growth Rate is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current 3-Year Dividend Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProPhase Labs Business Description

Address 626 RXR Plaza, 6th Floor, Uniondale, NY, USA, 11556
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.